ストックスクリーナーアプリを入手
8.25
0.86%
0.07
Altimmune Inc (ALT) 最新ニュース
Altimmune’s Nasdaq Biotech Index Addition Fuels Retail Enthusiasm, Stock Rebounds - MSN
Altimmune (ALT) Gains on Nasdaq Biotechnology Index Inclusion - GuruFocus.com
Why Altimmune Was Such a Robustly Healthy Stock on Thursday - MSN
Altimmune (NASDAQ:ALT) Trading 4.7% HigherTime to Buy? - MarketBeat
Altimmune joins Nasdaq Biotechnology Index - Investing.com
Altimmune Joins Nasdaq Biotechnology Index, Gears Up for Pivotal MASH Drug Trial Data in 2025 - StockTitan
(ALT) Trading Report - Stock Traders Daily
Altimmune (NASDAQ:ALT) Stock Price Down 5.1%Should You Sell? - MarketBeat
Altimmune's SWOT analysis: pemvidutide's potential reshapes obesity stock outlook - Investing.com
Biodefense Market CAGR of 7.3% Size, Growth Drivers and Forecast 2024-2031 | XOMA corporation, Altimmune Inc., - EIN News
Altimmune 2025: Redefining Obesity And MASH Treatment (NASDAQ:ALT) - Seeking Alpha
Virtu Financial LLC Makes New $674,000 Investment in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Altimmune (NASDAQ:ALT) Shares Up 4.9%Still a Buy? - MarketBeat
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Altimmune reports positive trial results for liver disease drug By Investing.com - Investing.com Nigeria
Altimmune reports positive trial results for liver disease drug - Investing.com India
Trend Tracker for (ALT) - Stock Traders Daily
Altimmune Stock Up More Than 25% in a Month: Here's Why - MSN
Portolan Capital Management LLC Sells 579,266 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Altimmune's SWOT analysis: pemvidutide's potential reshapes obesity and NASH stock outlook By Investing.com - Investing.com South Africa
Altimmune's SWOT analysis: pemvidutide's potential reshapes obesity and NASH stock outlook - Investing.com Canada
Looking At Altimmune's Recent Unusual Options Activity - Benzinga
Altimmune shares surge on CEO's CNBC appearance By Investing.com - Investing.com Canada
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On WednesdayAltimmune (NASDAQ:ALT), Bitdeer Technologies (NASDAQ:BTDR) - Benzinga
Altimmune CEO on what’s next for its experimental obesity drug - CNBC
Altimmune Stock Up More Than 25% In A Month: Here's Why - Barchart
Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders - The Manila Times
Altimmune CMO to Present Key Obesity Drug Data at Major Medical Conference - StockTitan
Altimmune, Inc. (NASDAQ:ALT) Stake Lifted by Bellevue Group AG - MarketBeat
How To Trade (ALT) - Stock Traders Daily
Altimmune to Participate at Two Upcoming Investor Conferences - The Manila Times
Altimmune to Present at Evercore and Piper Sandler Healthcare Conferences in December | ALT Stock News - StockTitan
Altimmune (ALT) Price Target Increased by 16.42% to 22.73 - MSN
Do Redditors Think That Altimmune Inc. (ALT) Has a Big Upside Potential? - Insider Monkey
11 Reddit Stocks with Biggest Upside Potential - Insider Monkey
FY2024 EPS Estimates for Altimmune Reduced by HC Wainwright - MarketBeat
Altimmune, Inc. (NASDAQ:ALT) Receives $20.00 Consensus Target Price from Analysts - MarketBeat
Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024 - Marketscreener.com
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 - The Manila Times
What is B. Riley's Forecast for Altimmune FY2024 Earnings? - MarketBeat
Altimmune's Pemvidutide Shows 68.5% Liver Fat Reduction in Phase 1b Trial Results - StockTitan
AMERIPRISE FINANCIAL INC's Strategic Acquisition in Altimmune Inc - GuruFocus.com
B. Riley Weighs in on Altimmune's Q1 Earnings (NASDAQ:ALT) - MarketBeat
Altimmune (NASDAQ:ALT) Given Buy Rating at HC Wainwright - MarketBeat
Altimmune Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):